Januvia (sitagliptin) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 148 Diseases   56 Trials   56 Trials   3630 News 


«12345678910111213...4041»
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Renal Limited Sarcoidosis Presenting as Granulomatous Interstitial Nephritis (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3524;    
    A review of literature revealed about 100 cases of renal sarcoid associated GIN but majority had extra renal manifestations. The mainstay of therapy for sarcoidosis with GIN is steroids.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With CKD and Type 2 Diabetes (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2119;    
    We evaluated the comparative safety of SGLT2i versus glucagon-like peptide 1 receptor agonist (GLP-1RA) or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin among patients with CKD and type 2 diabetes (T2D) in routine care...Conclusion In U.S. patients with CKD and T2D from routine care, with older mean age than those in RCTs, SGLT2i are associated with increased risks of lower limb amputations, genital infections, and potentially non-vertebral fractures, and with lower risks of hyperkalemia and acute kidney injury. No differences were observed for diabetic ketoacidosis, hypovolemia, and hypoglycemia.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Procalcitonin mediates vascular dysfunction in obesity. (Pubmed Central) -  Oct 13, 2022   
    Procalcitonin, liberated either from visceral or perivascular adipose tissue, contributes to endothelial dysfunction by antagonizing CGRP signaling in obesity. Targeting hyperprocalcitonemia may be a means to preserve endothelial function and reduce comorbidity burden in obese subjects.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
    Observational data, Retrospective data, Journal, HEOR, Real-world evidence:  Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. (Pubmed Central) -  Oct 10, 2022   
    In this emulation of the GRADE trial, liraglutide was statistically significantly more effective at maintaining glycemic control than glimepiride or sitagliptin when added to metformin monotherapy. Generating timely evidence on medical treatments using real world data as a complement to prospective trials is of value.
  • ||||||||||  Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
    COVID-19 vaccine-related liver injury: A possible emerging association () -  Oct 4, 2022 - Abstract #AGW2022AGW_399;    
    We wish to strongly emphasize that cases such as these should not be a deterrent to COVID-19 vaccination, and infection with SARS-CoV-2 itself has been linked to the development of hepatitis. Rather, these cases add to a slowly mounting body of evidence for a possible association, and clinicians should be mindful of this when assessing patients presenting with abnormal liver enzymes after recent COVID-19 vaccination.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy? (Pubmed Central) -  Oct 2, 2022   
    In conclusion, the DPP-4 receptor is regarded as a potential receptor for the binding and entry of SARS-CoV-2. Inhibition of these receptors by the DPP-4 inhibitor, sitagliptin, can reduce the pathogenesis of the infection caused by SARS-CoV-2 and their associated activation of the inflammatory signaling pathways.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. (Pubmed Central) -  Sep 29, 2022   
    P3
    However, glargine and liraglutide were significantly, albeit modestly, more effective in achieving and maintaining target glycated hemoglobin levels. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; GRADE ClinicalTrials.gov number, NCT01794143.).
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. (Pubmed Central) -  Sep 29, 2022   
    P3
    The findings indicated possible differences among the groups in the incidence of any cardiovascular disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; GRADE ClinicalTrials.gov number, NCT01794143.).
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. (Pubmed Central) -  Sep 24, 2022   
    This estimate was expressed relative to the maximal potential contribution of GIP to the effect of sitagliptin (= 100%), defined as the difference between the full sitagliptin treatment effect, including actions mediated by GIP (sitagliptin plus saline) and the physiological response minus any contribution by GIP (placebo treatment plus GIP(3-30)NH2). We demonstrate insulinotropic and glucose-lowering effects of endogenous GIP in patients with type 2 diabetes, and that endogenous GIP contributes to the improved beta cell function observed during DPP-4 inhibition.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Review, Journal:  Recent progress in the chemistry of β-aminoketones. (Pubmed Central) -  Sep 23, 2022   
    Also, the synthesis of the investigated compounds is accomplished by condensation reactions, from propargylic alcohols, reductive hydroamination, alkylation, carbonylative coupling, and acid hydrolysis of metal complexes. The aim of this review is to provide details for the synthesis of piperidines, morpholinones, piperazinones, dihydroxy-2-oxopyrroles, spirocyclic systems, imidazolines, indolizines, pyrido-isoindoles, aminoalcohols, metal complexes, fluoxetine, sotolon, (S)-ketamine, indolines, and benzoazepinones.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
    Review, Journal:  Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus. (Pubmed Central) -  Sep 18, 2022   
    It seems that both groups may be successful in the GDM management used alone or as an addition to better-known drugs, including metformin and glyburide. However, more clinical trials are needed to confirm their importance in GDM treatment and to demonstrate effective therapeutic strategies.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease. (Pubmed Central) -  Sep 16, 2022   
    P=N/A
    Sitagliptin improves abnormalities in glucose metabolism, but not reduces the IHL in T2DM with NAFLD, indicating that sitagliptin might be a therapeutic option for treatment of NAFLD indirectly while not directly on IHL. Clinical Trial Registration: https://clinicaltrials.gov/, identifier CTR# NCT05480007.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Patient preferences for newer Oral therapies in type 2 diabetes. (Pubmed Central) -  Sep 14, 2022   
    While the drug profile comparable to empagliflozin was preferred, CV benefit was not the top patient priority. A shared physician-patient decision model and increased patient education are needed to ensure optimal use of guideline-directed T2DM therapies.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Anti-glycemic potential of benzophenone thio/semicarbazone derivatives: synthesis, enzyme inhibition and ligand docking studies. (Pubmed Central) -  Sep 14, 2022   
    The binding sites as well as affinity of active compounds for DPP- IV enzyme were predicted by in silico studies, and compared to a standard drug, sitagliptin...Compound 9 showed the highest inhibitory activity (IC = 15.0 ± 0.6 µM), whereas compounds 10, 17, 12, 14 and 23 showed a moderate activity with IC values in the range of 28.9-39.2 µM. This study identifies thio- and semicarbazones as new classes of DPP-IV inhibitors which may translate into safe and effective therapeutics for a better management of type 2 diabetes.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  Sugarnon (evogliptin) - Dong / A
    Clinical, Retrospective data, Review:  The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis. (Pubmed Central) -  Sep 14, 2022   
    P = 0.966) regarding the adverse effects, indicating no significant difference between evogliptin and linagliptin or sitagliptin in affecting the HbA1c level and adverse effects. The study provides preliminary evidence regarding the similarity in the efficacy of evogliptin compared to other DPP-4i drugs, including sitagliptin and linagliptin, for managing HbA1c levels and adverse events.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Retrospective data, Review, Journal:  Efficacy and safety of sitagliptin and insulin for latent autoimmune diabetes in adults: a systematic review and meta-analysis. (Pubmed Central) -  Sep 10, 2022   
    Sitagliptin combined with insulin can achieve better glycemic control and improve islet β-cell function with lower incidence of hypoglycemia compared with insulin alone, which provides an effective and tolerated therapeutic regimen for LADA patients. However, further well-designed and rigorous randomized controlled trials are required to validate this benefit due to the limited methodology quality of included trials.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. (Pubmed Central) -  Sep 10, 2022   
    P4
    The glucose-lowering effects of long-term sacubitril/valsartan treatment reported in patients with heart failure and type 2 diabetes may not depend on changes in entero-pancreatic hormones. Neprilysin inhibition results in hyperglucagonaemia and this may explain the worsen glucose tolerance observed in this study.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Vesicles of yeast cell wall-sitagliptin to alleviate neuroinflammation in Alzheimer's disease. (Pubmed Central) -  Sep 3, 2022   
    Brain concentration of the nanoparticles group remained approximately unchanged, proving the "Trojan Horse" effect of the developed nanocarriers. The results are promising for using yeast-cell wall as a carrier for targeted delivery to immune cells for the management of inflammation.
  • ||||||||||  Journal:  Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment. (Pubmed Central) -  Aug 27, 2022   
    Glimepiride may be used in this population to attain glycemic control, particularly in settings where cost of DPP4Is is a concern. Patients with T2DM in the USA are significantly more likely to prefer oral or injectable semaglutide-like profiles over those of key comparators from the glucagon-like peptide 1 receptor agonist, sodium-glucose cotransporter 2 inhibitor, dipeptidyl peptidase 4 inhibitor, and thiazolidinedione classes.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Trial completion:  SITAGRAMI: Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction (clinicaltrials.gov) -  Aug 25, 2022   
    P2/3,  N=174, Completed, 
    Patients with T2DM in the USA are significantly more likely to prefer oral or injectable semaglutide-like profiles over those of key comparators from the glucagon-like peptide 1 receptor agonist, sodium-glucose cotransporter 2 inhibitor, dipeptidyl peptidase 4 inhibitor, and thiazolidinedione classes. Unknown status --> Completed
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Targeting Procalcitonin Protects Vascular Barrier Integrity. (Pubmed Central) -  Aug 22, 2022   
    This process may be affected by DPP4 inhibition. Targeting procalcitonin's action on the endothelium is a feasible means to preserve vascular integrity during systemic inflammation associated with hyperprocalcitonemia.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    A Bariatric Surgery Derived Gut Metabolite Is a Potent Single and Combination Oral Therapy for Type 2 Diabetes (T2D). (SDCC - 6E - Upper) -  Aug 21, 2022 - Abstract #ACSCLINCON2022ACS_CLINCON_1400;    
    Our results indicate that the autoantibodies against the linear full-length BP180 are common in patients with T2D, but seropositivity is unaffected by the use of sitagliptin. Single and combination therapy of CA7S, a surgically induced, gut-restricted metabolite and sitagliptin improves glucose tolerance and augments GLP-1 secretion.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Socioeconomic status and public health in Australia: A wastewater-based study. (Pubmed Central) -  Aug 18, 2022   
    Furthermore, it can identify specific areas and socioeconomic groups that may need more assistance than others for public health issues. This approach complements important public health information and enables large-scale national coverage with a relatively small number of samples.
  • ||||||||||  prusogliptin (DBPR108) / CSPC Pharma
    Trial completion, Trial completion date, Trial primary completion date:  A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (clinicaltrials.gov) -  Aug 17, 2022   
    P3,  N=766, Completed, 
    This approach complements important public health information and enables large-scale national coverage with a relatively small number of samples. Recruiting --> Completed | Trial completion date: Jun 2024 --> Jun 2022 | Trial primary completion date: Apr 2024 --> Jun 2022
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients. (Pubmed Central) -  Aug 17, 2022   
    Furthermore, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination experiments in healthy mice demonstrated that supplementation of gly-pro down-regulates SARS-CoV-2-specific receptor-binding domain antibody levels and suppresses immune responses, whereas the DPP4 inhibitor sitagliptin can counteract the inhibitory effects of gly-pro upon SARS-CoV-2 vaccination. Our findings not only reveal the important role of gly-pro in the immune responses to SARS-CoV-2 infection but also indicate a possible mechanism underlying the beneficial outcomes of treatment with DPP4 inhibitors in convalescent COVID-19 patients, shedding light on therapeutic and vaccination strategies against COVID-19.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, avexitide (exendin 9-39) / Eiger, Januvia (sitagliptin) / Merck (MSD)
    Enrollment change:  Cardiovascular Effects of GLP-1 Receptor Activation (clinicaltrials.gov) -  Aug 16, 2022   
    P4,  N=329, Completed, 
    [https://www.irct.ir/trial/46140], identifier [IRCT20140430017505N2]. N=88 --> 329